Fundraising Fox

Deciduous Therapeutics

San Francisco, US · Founded 2018 · Delaware corporation · 7 known investors

deciduoustx.com ↗

Deciduous Therapeutics develops small molecule and immunomodulatory therapies targeting senescent cells to treat age-related diseases including Type 1 diabetes, autoimmunity, and metabolic disorders. The company serves patients with conditions driven by cellular aging and senescence.

BiotechDigital HealthLongevity

Founders & leadership

RM
Robin MansukhaniinCEO and Co-Founder
AB
Anil BhushaninScientific Founder
DM
Dylan MorrisinDirector

Investors · 7

age1San Francisco · $500K – $4M
Bold Capital PartnersSanta Monica
Cornucopian Capital ManagementMontclair
CRV (Charles River Ventures)Bay Area · $250K – $5M
Owl Capitalvia Jennifer Fonstad · inferred
quadraScope Venture FundBoston
Axial VCreportedSan Francisco · $100K – $5M

Reported raises · per SEC filings

Form D private placements
▶$5.8MraisedJul 2019 · 10 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Robin MansukhaniExecutive Officer, Director
  • Dylan MorrisDirector
  • Anil BhushanDirector
Offering amount
$6.5M
Amount sold
$5.8M
Minimum investment
$10K
First sale
Jun 2019
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.